Takeda Pharmaceutical Co Ltd (4502):企業の財務・戦略的SWOT分析

◆英語タイトル:Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C12051
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:77
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Takeda Pharmaceutical Co Ltd (4502) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Takeda Pharmaceutical Company Ltd (Takeda) is a research-based global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products. The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics. Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia. It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India. It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore. Takeda is headquartered in Chuo-ku, Osaka, Japan.

Takeda Pharmaceutical Co Ltd Key Recent Developments

Dec 04,2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
Dec 03,2018: Riassunto: Takeda presenter dati positivi da TOURMALINE-MM3, il primo studio pivot di fase 3 controllato con placebo per la valutazione di un trattamento con inibitore del proteasoma nell’ambito di una terapia di mantenimento
Dec 02,2018: Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting
Dec 02,2018: Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting
Nov 22,2018: Takeda Voluntary Recalls 7 Narcotic Injectable Products after Confirming Coloring

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Takeda Pharmaceutical Co Ltd – Key Facts 6
Takeda Pharmaceutical Co Ltd – Key Employees 7
Takeda Pharmaceutical Co Ltd – Key Employee Biographies 8
Takeda Pharmaceutical Co Ltd – Major Products and Services 9
Takeda Pharmaceutical Co Ltd – History 11
Takeda Pharmaceutical Co Ltd – Company Statement 27
Takeda Pharmaceutical Co Ltd – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Joint Venture 35
Section 2 – Company Analysis 37
Company Overview 37
Takeda Pharmaceutical Co Ltd – Business Description 38
Business Segment: Pharmaceutical Products 38
Overview 38
Performance 38
Geographical Segment: Asia 39
Performance 39
Geographical Segment: Europe and Canada 39
Performance 39
Geographical Segment: Japan 39
Performance 39
Geographical Segment: Latin America 39
Performance 39
Geographical Segment: Other 39
Performance 39
Geographical Segment: Russia/CIS 39
Performance 39
Geographical Segment: The US 39
Performance 39
Takeda Pharmaceutical Co Ltd – SWOT Analysis 40
SWOT Analysis – Overview 40
Takeda Pharmaceutical Co Ltd – Strengths 40
Takeda Pharmaceutical Co Ltd – Weaknesses 41
Takeda Pharmaceutical Co Ltd – Opportunities 42
Takeda Pharmaceutical Co Ltd – Threats 43
Takeda Pharmaceutical Co Ltd – Key Competitors 44
Section 3 – Company Financial Ratios 45
Financial Ratios – Capital Market Ratios 45
Financial Ratios – Annual Ratios 46
Performance Chart 49
Financial Performance 49
Financial Ratios – Interim Ratios 50
Financial Ratios – Ratio Charts 51
Section 4 – Company’s Lifesciences Financial Deals and Alliances 52
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53
Takeda Pharmaceutical Co Ltd, Recent Deals Summary 54
Section 5 – Company’s Recent Developments 55
Dec 04, 2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas 55
Dec 04, 2018: Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas 57
Nov 21, 2018: Takeda gets conditional EC approval for $62bn Shire acquisition 59
Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 60
Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 62
Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 64
Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 66
Nov 07, 2018: Takeda Launches Entyvio in Japan for Ulcerative Colitis 68
Nov 01, 2018: Riassunto: Takeda presenter dati su una vasta gamma di esigenze di trattamento per i tumori del sangue al 60 congresso annuale dell’American Society of Hematology 70
Oct 31, 2018: Takeda reports second quarter FY2018 results 71
Section 6 – Appendix 73
Methodology 73
Ratio Definitions 73
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Takeda Pharmaceutical Co Ltd, Key Facts 6
Takeda Pharmaceutical Co Ltd, Key Employees 7
Takeda Pharmaceutical Co Ltd, Key Employee Biographies 8
Takeda Pharmaceutical Co Ltd, Major Products and Services 9
Takeda Pharmaceutical Co Ltd, History 11
Takeda Pharmaceutical Co Ltd, Other Locations 28
Takeda Pharmaceutical Co Ltd, Subsidiaries 29
Takeda Pharmaceutical Co Ltd, Joint Venture 35
Takeda Pharmaceutical Co Ltd, Key Competitors 44
Takeda Pharmaceutical Co Ltd, Ratios based on current share price 45
Takeda Pharmaceutical Co Ltd, Annual Ratios 46
Takeda Pharmaceutical Co Ltd, Annual Ratios (Cont...1) 47
Takeda Pharmaceutical Co Ltd, Annual Ratios (Cont...2) 48
Takeda Pharmaceutical Co Ltd, Interim Ratios 50
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 53
Takeda Pharmaceutical Co Ltd, Recent Deals Summary 54
Currency Codes 73
Capital Market Ratios 73
Equity Ratios 74
Profitability Ratios 74
Cost Ratios 75
Liquidity Ratios 75
Leverage Ratios 76
Efficiency Ratios 76

List of Figures
Takeda Pharmaceutical Co Ltd, Performance Chart (2014 - 2018) 49
Takeda Pharmaceutical Co Ltd, Ratio Charts 51
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 52
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 53

★海外企業調査レポート[Takeda Pharmaceutical Co Ltd (4502):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Boule Diagnostics AB (BOUL):医療機器:M&Aディール及び事業提携情報
    Summary Boule Diagnostics AB (Boule) is a medical device company that offers hematology diagnostic solutions. The company provides systems and consumer products for complete blood counts to non-institutional healthcare. It offers products such as blood cell counter and instruments, reagents, calibra …
  • Tata Chemicals Ltd (TATACHEM):企業の財務・戦略的SWOT分析
    Summary Tata Chemicals Ltd (TCL) is a chemical company engaged in offering industry, living, and farm essential chemicals. The company's products include dals, consumer salt, water purifier, soda ash, spices, sodium bicarbonate, allied chemicals, industrial salt, customized fertilizers, cement, fert …
  • The Cheesecake Factory Incorporated:企業の戦略・SWOT・財務情報
    The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Ingram Entertainment Inc.:企業の戦略・SWOT・財務情報
    Ingram Entertainment Inc. - Strategy, SWOT and Corporate Finance Report Summary Ingram Entertainment Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • GridPoints Inc:企業の戦略的SWOT分析
    GridPoints Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Canadian Natural Resources Ltd (CNQ):石油・ガス:M&Aディール及び事業提携情報
    Summary Canadian Natural Resources Ltd (Canadian Natural) is an independent upstream oil and gas company. The company carries out acquisition, exploration, development, production, marketing and sale of crude oil, natural gas and natural gas liquids (NGLs). Canadian Natural’s products include light …
  • Sumitomo Chemical Co Ltd (4005):企業の財務・戦略的SWOT分析
    Sumitomo Chemical Co Ltd (4005) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • GEE Group Inc (JOB):企業の財務・戦略的SWOT分析
    Summary GEE Group Inc (GEE) is a provider of professional staffing and recruiting services. The company’s staffing services comprise temporary staffing services, professional placement services, and management services. It provides direct hire, contract, and contract-to-hire services in accounting, …
  • Australian Mines Limited:企業の戦略・SWOT・財務分析
    Australian Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Vietnam Technological and Commercial Joint Stock Bank (TCB):企業の財務・戦略的SWOT分析
    Vietnam Technological and Commercial Joint Stock Bank (TCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the comp …
  • Identiv Inc (INVE):企業の財務・戦略的SWOT分析
    Summary Identiv Inc (Identiv), formerly Identive Group Inc, is a technology company that offers physical security and secure identification solutions. The company’s products include trusted authentication solutions, identity solutions, physical access control solutions, premises access solutions, co …
  • Aderans Co Ltd:企業の戦略・SWOT・財務分析
    Aderans Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Aderans Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Rolta India Ltd (ROLTA):企業の財務・戦略的SWOT分析
    Rolta India Ltd (ROLTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Diamond Offshore Drilling, Inc.:企業の戦略・SWOT・財務情報
    Diamond Offshore Drilling, Inc. - Strategy, SWOT and Corporate Finance Report Summary Diamond Offshore Drilling, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • CytomX Therapeutics Inc (CTMX):企業の財務・戦略的SWOT分析
    Summary CytomX Therapeutics Inc (CytomX) is a clinical-stage biopharmaceutical company which develops novel therapeutic antibodies and Probody therapeutics for the treatment of cancer. The company’s leading product candidates include CX-072, CX-2009, BMS-986249, CX-2029, CX-188, probody drug conjuga …
  • Ca Immobilien Anlagen Ag:企業の戦略・SWOT・財務分析
    Ca Immobilien Anlagen Ag - Strategy, SWOT and Corporate Finance Report Summary Ca Immobilien Anlagen Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Statnett SF:企業の戦略的SWOT分析
    Statnett SF - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Bruker Corporation:企業の戦略・SWOT・財務情報
    Bruker Corporation - Strategy, SWOT and Corporate Finance Report Summary Bruker Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • SOCO International Plc (SIA):石油・ガス:M&Aディール及び事業提携情報
    Summary SOCO International Plc (SOCO) is an oil and gas company that explores, discovers and produces oil and gas reserves. The company offers appraisal and field development services. It provides training and skills and support local communities. SOCO produces and supplies natural resources. SOCO h …
  • Banco Hipotecario SA (BHIP3):企業の財務・戦略的SWOT分析
    Banco Hipotecario SA (BHIP3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆